Midwestern University Home

Marc H. Scheetz, Pharm.D., MSc, BCPS-AQID

Associate Professor


Dr. Marc Scheetz

 

Associate Professor
Midwestern University Chicago College of Pharmacy
555 31st Street
Alumni Hall, 381
Downers Grove, IL 60515 

 
Infectious Diseases Pharmacist
Northwestern Memorial Hospital
251 E. Huron St.
Feinberg Pavilion, LC 700
Chicago, IL 60611

Email:  mschee@midwestern.edu; mscheetz@nmh.org

Other Websites:

 https://www.researchgate.net/profile/Marc_Scheetz/ 

http://www.linkedin.com/pub/marc-scheetz/6/244/b39

Fellowship Information, recruiting one fellow per year, starting July 2014:
http://www.midwestern.edu/programs-and-admission/il-pharmacy/admissionapply/residencyfellowship-programs/pgy23-infectious-diseases-fellowship.html


 

Biosketch

Dr. Marc Scheetz attained a Doctorate of Pharmacy from Butler University, earned a Masters of Science in Clinical Investigation degree at Northwestern University, and completed his pharmacy practice residency and an infectious diseases fellowship at Northwestern Memorial Hospital. Dr. Scheetz is an Associate Professor at Midwestern University Chicago College of Pharmacy where he serves as an instructor in pharmacokinetics. He currently practices clinically as an infectious diseases pharmacist at Northwestern Memorial Hospital in downtown Chicago, IL and serves as the director/site coordinator for two postdoctoral pharmacy programs in the specialty of infectious diseases pharmacotherapy.   

Dr. Scheetz has authored a number of original research manuscripts and review articles in the area of anti-infective pharmacokinetics and pharmacodynamics and currently serves as a reviewer for several infectious diseases and pharmacy medical journals. His primary research interest is in the ecology of antimicrobial resistance as it pertains to the pharmacokinetic/pharmacodynamic interaction between antimicrobials, pathogens, and hosts. He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases.  He is actively engaged in local and national leadership positions.  He was recently appointed to the FDA Anti-Infective Drugs Advisory Committee.

 

 

Select Publications (out of 62 peer reviewed manuscripts)

1.            McLaughlin M, Malczynski M, Qi C, Barajas G, Radetski J, Zembower T, Scheetz MH. Virulence of vancomycin-resistant Enterococcus faecium according to linezolid resistance and clinical outbreak status. Antimicrob Agents Chemother. 2013;57(8):3923-7. Epub 2013/06/05. doi: 10.1128/AAC.00192-13. PubMed PMID: 23733458; PubMed Central PMCID: PMC3719778.

2.            McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131-3. Epub 2013/07/10. doi: 10.1128/AAC.00607-13. PubMed PMID: 23836188.

3.            Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH. Pharmacodynamic Target Attainment for Various Ceftazidime Dosing Schemes in High-flux Hemodialysis. Antimicrob Agents Chemother. 2013. Epub 2013/09/11. doi: 10.1128/AAC.00474-13. PubMed PMID: 24018264.

4.            Leung E, Venkatesan N, Ly SC, Scheetz MH. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. Am J Health Syst Pharm. 2013;70(13):1163-6. Epub 2013/06/21. doi: 10.2146/ajhp120409. PubMed PMID: 23784164.

5.            Griffith MM, Gross AE, Sutton SH, Bolon MK, Esterly JS, Patel JA,Scheetz MH. The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. Clin Infect Dis. 2012;54(5):684-91. Epub 2012/01/24. doi: 10.1093/cid/cir954. PubMed PMID: 22267747.

6.            Esterly JS, Wagner J, McLaughlin MM, Postelnick MJ, Qi C, Scheetz MH. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother. 2012;56(9):4885-90. Epub 2012/07/11. doi: 10.1128/AAC.06365-11. PubMed PMID: 22777044; PubMed Central PMCID: PMC3421845.

7.            Scheetz MH, Bolon MK, Esterly JS, Reddy P, Postelnick M, Lee TA. Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. Pharmacotherapy. 2011;31(5):469-79. Epub 2011/09/20. doi: 10.1592/phco.31.5.469. PubMed PMID: 21923428.

8.            Gorski E, Esterly JS, Postelnick M, Trifilio S, Fotis M, Scheetz MH. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother. 2011;55(1):184-9. Epub 2010/10/27. doi: 10.1128/AAC.01078-10. PubMed PMID: 20974867; PubMed Central PMCID: PMC3019689.

9.            Esterly J, Richardson CL, Eltoukhy NS, Qi C, Scheetz MH. Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii (February). The Annals of pharmacotherapy. 2011. Epub 2011/02/10. doi: 10.1345/aph.1P084. PubMed PMID: 21304033.

10.          Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, Scheetz MH. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother. 2010;54(4):1534-40. Epub 2010/01/21. doi: 10.1128/AAC.01111-09. PubMed PMID: 20086152; PubMed Central PMCID: PMC2849391.

11.          Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009;64(3):311-9. Epub 2009/04/07. doi: 10.1016/j.diagmicrobio.2009.02.006. PubMed PMID: 19345039; PubMed Central PMCID: PMC2693471.

12.          Scheetz MH, Esterly JS, Malczynski M, Postelnick M, Qi C. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2009;64(4):465-7. Epub 2009/04/28. doi: 10.1016/j.diagmicrobio.2009.03.017. PubMed PMID: 19394788.

13.          Defife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother. 2009;53(3):1074-9. Epub 2008/12/17. doi: 10.1128/AAC.00580-08. PubMed PMID: 19075047; PubMed Central PMCID: PMC2650520.

14.          Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52(6):2256-9. Epub 2008/04/09. doi: 10.1128/AAC.00070-08. PubMed PMID: 18391028; PubMed Central PMCID: PMC2415807.

15.          Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(5):1621-6. Epub 2007/02/20. doi: 10.1128/AAC.01099-06. PubMed PMID: 17307973; PubMed Central PMCID: PMC1855572. 

Disclaimer: Any information contained here is not intended as a substitute for professional medical advice, emergency treatment or formal training. Don't use this information to diagnose or develop a treatment plan for a health problem or disease without consulting a qualified health care provider. If you're in a life-threatening or emergency medical situation, seek medical assistance immediately. Moreover, the site is not intended to be, and you understand and agree that it does not constitute, the provision or practice of medical, nursing, or professional health care advice or services in any jurisdiction.   


Bookmark and Share